Noom vs Medvi: Compare GLP-1 Weight Loss Programs

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Noom and Medvi serve different niches in the weight-loss medication space. Noom, launched in 2008, emphasizes behavioral psychology and cognitive techniques alongside optional GLP-1 integration, reaching approximately 5 million users. Medvi, a telehealth platform founded more recently, positions itself as a direct-to-consumer GLP-1 prescription service with streamlined prescribing. Both address metabolic weight loss, but through fundamentally different clinical models and patient engagement strategies.

Choosing between Noom vs Medvi depends on whether you prioritize behavioral support with optional medication or direct GLP-1 access with minimal coaching overhead. This distinction matters clinically—behavioral interventions may enhance medication adherence and durability, while direct prescribing offers rapid access. PlexusDx complements either approach by offering compounded GLP-1 formulations and a Precision Peptide Genetic Test to help providers personalize dosing and formulation based on metabolic pathway variants.

Understanding Noom's Behavioral-First Model

Noom operates as a digital wellness platform combining cognitive behavioral therapy principles with daily food logging, habit tracking, and personal coaching. Users interact with a paid app (typically $59–$199/month) and receive asynchronous coach feedback. The behavioral layer is primary; GLP-1 medications are offered as an add-on through Noom's telehealth partnerships, not as the core service.

Clinical evidence supports behavioral interventions for weight loss sustainability. Noom's approach acknowledges that medication alone addresses appetite but not eating patterns or psychological drivers. This model appeals to users seeking holistic lifestyle change alongside pharmacotherapy, though it requires sustained engagement and daily app use.

Medvi's GLP-1-Centered Prescribing Model

Medvi streamlines the patient journey by focusing primarily on GLP-1 prescription and delivery. Users complete a medical questionnaire, consult briefly with a provider, and receive branded or compounded GLP-1 injections or oral formulations mailed to their home. Medvi's cost structure typically ranges from $250–$350/month for medication plus consultation fees, with minimal ongoing coaching.

This direct-prescribing model reduces friction for patients motivated by pharmacotherapy alone. Medvi does not mandate behavioral coaching, appealing to users who prefer autonomy or already practice self-directed nutrition changes. However, clinical outcomes may depend partly on individual adherence without structured behavioral support.

Clinical Comparison Framework: Noom vs Medvi

Both platforms address obesity through medication, yet their clinical designs differ substantially. The table below highlights key operational, clinical, and accessibility differences that may inform provider or patient choice.

Factor	Noom	Medvi
Primary Focus	Behavioral psychology + optional GLP-1	Direct GLP-1 prescription and delivery
Medication Integration	Add-on through partner telehealth	Core service offering
Ongoing Coaching	Daily app interaction + coach feedback	Minimal ongoing support; self-directed
Approximate Monthly Cost	$59–$199 (app) + medication costs	$250–$350 + consultation fees
User Engagement Requirement	High (daily logging and coaching)	Low (medication delivery focused)
Medication Options	Branded GLP-1s via partners	Branded or compounded formulations

Behavioral Interventions and Medication Durability

Research suggests behavioral interventions enhance GLP-1 efficacy and weight-loss maintenance. Patients who engage in structured coaching or cognitive behavioral therapy alongside medication show better adherence and smaller rebound weight gains after discontinuation. Noom's emphasis on habit formation and psychological patterns may provide durability advantages over medication-only approaches.

Medvi's lean model prioritizes access and simplicity but assumes patients possess self-regulation skills or ongoing external accountability. Some individuals thrive with minimal supervision; others benefit from structured behavioral scaffolding. Clinical outcomes likely depend on baseline motivation, prior weight-loss history, and individual psychology—neither model is universally superior.

Provider Decision Framework for GLP-1 Selection

Healthcare providers evaluating Noom vs Medvi should consider patient phenotype. Patients with identified eating disorders, binge-eating behaviors, or high stress-eating should be directed toward behavioral support models like Noom or similar programs with licensed mental health integration. Patients with straightforward appetite dysregulation and strong self-directed motivation may achieve similar outcomes via Medvi's prescribing pathway.

Neither Noom nor Medvi currently integrate genetic pathway assessment into personalization. Both rely on standard clinical criteria (BMI, comorbidities, prior medication trials) for eligibility. Providers seeking pharmacogenetic or peptide-pathway insights to guide formulation and dosing must look beyond these platforms.

Genetic Pathway Insights and Precision Personalization

Emerging evidence highlights variability in GLP-1 receptor signaling, GIPR pathway responsiveness, and FTO-related metabolic predispositions across individuals. These genetic factors may influence baseline GLP-1 sensitivity, optimal formulation choice (injection vs. oral), and microdose vs. standard-dose protocols. PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways to provide context for provider conversations about personalized dosing strategies.

While Noom and Medvi offer medication access, neither incorporates peptide-pathway genetic assessment into their clinical workflow. A genetic report may help providers and patients understand why one formulation, dosing strategy, or compound strength aligns better with individual metabolic architecture. This is not a guarantee of outcome—genetic predisposition provides context, not destiny—but can support informed prescribing conversations.

Safety, Eligibility, and Medical Supervision

Both Noom and Medvi require baseline medical screening, though depth varies. Noom's telehealth GLP-1 partners conduct standard cardiovascular and renal assessments; Medvi's providers similarly screen for contraindications (personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis risk). Neither replaces full in-person evaluation for high-risk patients.

GLP-1 medications carry real adverse effects: nausea, dehydration risk, rare pancreatitis, and potential cardiac or thyroid concerns in predisposed individuals. Patients should disclose complete medical histories and remain under provider supervision, particularly during titration. If side effects emerge, direct access to a prescribing provider (not behavioral coaches) is essential. PlexusDx partners with licensed 503A compounding pharmacies and providers for safety oversight comparable to branded alternatives.

How PlexusDx Supports a More Personalized Approach

PlexusDx's compounded GLP-1 options—including semaglutide injection, oral semaglutide, tirzepatide injection, and oral tirzepatide—provide flexible dosing and formulation choices that can align with individual metabolic predispositions. Unlike Noom or Medvi, which typically offer fixed branded dosing tiers, compounded protocols allow granular personalization from microdose to higher strengths, all prepared in licensed 503A pharmacies.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) examines your genetic variants in GLP1R, GIPR, FTO, and MC4R pathways—markers associated with baseline GLP-1 sensitivity, appetite-satiety signaling, and fat mass genetics. This test does not predict your exact medication response or guarantee weight loss; instead, it may help provide context for provider conversations about whether a microdose protocol, standard dosing, or an alternative compound might align with your genetic pathway profile.

If you're comparing Noom vs Medvi, consider asking your provider whether a genetic pathway assessment could inform your formulation choice. PlexusDx's combination of compounded flexibility and genetic context enables precision-guided conversations between you and your healthcare provider, supporting more individualized medication selection than fixed-platform offerings alone.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Noom and Medvi?

Noom prioritizes behavioral psychology and daily coaching with optional GLP-1 add-ons, while Medvi focuses on direct GLP-1 prescription and home delivery with minimal coaching. Choose Noom for structured lifestyle change; Medvi for streamlined medication access.

Is Noom or Medvi more clinically effective for weight loss?

Both can support weight loss; effectiveness depends on individual adherence and motivation. Noom's behavioral framework may improve durability; Medvi's direct prescribing suits self-directed users. Clinical outcomes vary by patient phenotype, not platform alone.

How much do Noom and Medvi cost per month?

Noom typically costs $59–$199/month (app) plus separate medication costs via partners. Medvi ranges $250–$350/month for medication and consultation. PlexusDx compounded GLP-1 starts at $129–$309/month depending on formulation, available after provider consultation.

Can I use Noom or Medvi if I have a history of eating disorders?

Patients with eating disorders require mental health oversight. Noom's behavioral coaching may be safer than Medvi's medication-only model, but both should involve licensed therapists or psychiatrists. Consult your mental health provider before starting any GLP-1 medication.

Does genetic testing improve GLP-1 medication selection?

Neither Noom nor Medvi use genetic pathway testing. PlexusDx's Precision Peptide Genetic Test examines GLP1R, GIPR, FTO, and MC4R variants to provide context for provider conversations about personalized dosing, though results do not guarantee outcomes or replace clinical judgment.

Noom vs Medvi: Clinical Models for GLP-1 Weight Management